Eiger BioPharmaceuticals (EIGR) Misses Q3 EPS by 10c

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q3 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $4.91 million.

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Movano (MOVE) Misses Q2 EPS by 195c